Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling

1 Feb 2017

Abstract excerpt

Cell division cycle 6 (CDC6), an androgen receptor (AR) target gene, is implicated in regulating DNA replication and checkpoint mechanisms. CDC6 expression is increased during prostate cancer (PCa) progression and positively correlates with AR in PCa tissues. AR or CDC6 knockdown, together with AZD7762, a Chk1/2 inhibitor, results in decreased TopBP1-ATR-Chk1 signaling and markedly increased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28228262
DOI: 10.1016/j.celrep.2017.01.072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 SignalingPMID 28228262Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancerSemantic proximity Read ↗

MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancerSemantic proximity Read ↗

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoverySemantic proximity Read ↗

Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell deathSemantic proximity Read ↗

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell LymphomasSemantic proximity Read ↗

Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous RecombinationSemantic proximity Read ↗

Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cellsSemantic proximity Read ↗

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we standSemantic proximity Read ↗

SR-4835, a CDK12 inhibitor, enhances the antitumor efficacy of sunitinib in human renal cell carcinoma through suppression of the ATR-associated DNA damage response pathway: an in vitro and in vivo studySemantic proximity Read ↗

A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progressionSemantic proximity Read ↗

Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.